N-butyl-3,5-dimethoxybenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-butyl-3,5-dimethoxybenzamide
• 化学式: C₁₃H₁₉NO₃
• mdl: MFCD01215855
• 分子量: 237.299
• InChiKey: AMVFIDNKEHIPPE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  47.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3,5-二甲氧基苯甲醛 、 正丁胺 在 二氧化碳 、 叔丁基过氧化氢 、 iron(II) chloride tetrahydrate 、 四丁基溴化铵 作用下， 以 水 、 乙腈 为溶剂， 反应 8.0h， 以78%的产率得到N-butyl-3,5-dimethoxybenzamide
  参考文献：
  名称：

  In situ protection and deprotection of amines for iron catalyzed oxidative amidation of aldehydes

  摘要：

  An environmentally friendly synthetic route by the application of CO2 to synthesize amides via in situ protection and deprotection of amines for iron catalyzed oxidative amidation of aldehydes was developed. Various secondary and tertiary amides have been synthesized in moderate to good yields under mild and neutral reaction conditions. The use of amine hydrochloride salts and hence base for neutralization step is totally avoided in this protocol. (C) 2015 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2015.08.066

文献信息

• QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS
  申请人：Collingwood Stephen Paul

  公开号：US20100041887A1

  公开（公告）日：2010-02-18

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的化合物，其以盐或双离子形式存在，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉乙酰胆碱M3受体介导的疾病。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• Quinuclidine derivatives binding to mucarinic m3 receptors
  申请人：Collingwood Paul Stephen

  公开号：US20070060563A1

  公开（公告）日：2007-03-15

  Compounds of formula I in salt or zwitterionic form wherein, wherein R 1 , R 2 , R 3 , and R 4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

  具有式I的盐或双电离形式的化合物，其中R1、R2、R3和R4的含义如规范中所示，可用于治疗由肌肉型M3受体介导的病症。还描述了含有这些化合物的制药组合物和制备这些化合物的过程。
• US8168654B2
  申请人：——

  公开号：US8168654B2

  公开（公告）日：2012-05-01
• In situ protection and deprotection of amines for iron catalyzed oxidative amidation of aldehydes
  作者：Thulasiram Bathini、Vikas S. Rawat、Sreedhar Bojja

  DOI：10.1016/j.tetlet.2015.08.066

  日期：2015.10

  An environmentally friendly synthetic route by the application of CO2 to synthesize amides via in situ protection and deprotection of amines for iron catalyzed oxidative amidation of aldehydes was developed. Various secondary and tertiary amides have been synthesized in moderate to good yields under mild and neutral reaction conditions. The use of amine hydrochloride salts and hence base for neutralization step is totally avoided in this protocol. (C) 2015 Elsevier Ltd. All rights reserved.